<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110809007265N15</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-01</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of laser and manual acupuncture in knee osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the clinical and immunological effectiveness of laser acupuncture, manual acupuncture, and sham in the treatment of knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/85121</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In the random allocation, we will use blocks of 6 and use the sealedenvelope  website. In this type of allocation, 16 blocks of 6 are generated by the system (2 of each letter) and are numbered from 1 to 90. The letters are placed in the order of their numbers in a matte envelope, the number is written on the envelope, and the lid is closed. People start taking the envelope in the order of their arrival from envelope number 1, open it, and are referred to the relevant group. In this way, people are placed equally in three groups. After the blocks are determined, they are placed in envelopes that cannot be seen from the outside, the letters are placed in them, and a number is written in order. People take the envelope in the order of their arrival and are assigned to the relevant group, Blinding description: All patients who enter the study first fill out an informed consent form, which states that the patient will be randomly assigned to one of three study groups: manual acupuncture, laser acupuncture, and the control group. Given that sham laser acupuncture is performed in the control group, patients in the laser acupuncture and control groups will be blinded to receiving the laser acupuncture intervention but will be aware that they will not receive conventional acupuncture. Patients in the manual acupuncture group will also likely notice the difference between this method and laser acupuncture, so blinding can only be done partially for the laser acupuncture and sham laser acupuncture groups. Blinding of the acupuncture specialist (principal investigator) is not possible. The referring rheumatologist, the nurse who takes the blood sample, the immunologist and expert, and the statistician will be responsible for collecting data and evaluating the outcomes for the assigned group of patients. The acupuncture resident responsible for data collection and overall patient follow-up will also be blinded to the assigned patient group.</study_design>
      <phase>3</phase>
      <hc_freetext>Gonarthrosis [arthrosis of knee].</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group: Manual acupuncture twice a week for 8 weeks. Intervention 2: Second Intervention group: Laser acupuncture twice a week for 8 weeks. Intervention 3: Control group: Sham laser twice a week for 8 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No decision has been made yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Hoda Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Fakouri Blvd., between Shahid Javan Sq. and Al Shahidi Sq., Mashhad, Khorasan Razavi Province</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177899191</zip>
        <telephone>+98 51 3879 5031</telephone>
        <email>AziziH@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Hoda Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Fakouri Blvd., between Shahid Javan Sq. and Al Shahidi Sq., Mashhad, Khorasan Razavi Province</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177899191</zip>
        <telephone>+98 51 3879 5031</telephone>
        <email>AziziH@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 45 and above
Patients with the diagnostic criteria of the American College of Rheumatology
Complaint of knee pain for more than 3 months
Radiological examination in the last 6 months indicating grade 2 or 3 of Kellgren lawrence with interpretation and confirmation by a respected rheumatologist
Patients with medial tibiofemoral osteoarthritis in at least one knee
A score of 4 or higher on the NSR
Do not consume omega-3 and glucosamine while studying
Not undergoing physiotherapy in the past three months
At the same time, they should not have another rheumatic disease such as rheumatoid arthritis</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Previous knee surgery on the knee being evaluated or pending any surgery for both knees
Knee pain caused by other pathologies (such as meniscus tear, rheumatoid arthritis, joint space infection, malignancy, gout, lumbosacral diseases with lower limb symptoms, etc.)
A history of arthroscopy within the last year or a history of intra-articular injection within the last 6 months for knee evaluation
Each of the knees has received acupuncture/physical therapy in the past 6 months
Severe acute or chronic organic or neuropsychiatric disorder
Coagulation disorders (such as hemophilia)
Autoimmune disorders
Malignancies
Patients with epilepsy or those with a pacemaker
Drug use
Physiotherapy a month ago
Preparation for pregnancy, pregnancy or breastfeeding period
Patients who have participated in other acupuncture clinical studies in the past month</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group: Manual acupuncture twice a week for 8 weeks</i_keyword>
      <i_keyword>Second Intervention group: Laser acupuncture twice a week for 8 weeks</i_keyword>
      <i_keyword>Control group: Sham laser twice a week for 8 weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: The trial duration is 16 weeks, including 8 weeks of treatment and 8 weeks of follow-up. Method of measurement: Pain based on Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Knee joint performance status. Timepoint: Before treatment, week 4, week 8, and week 16. Method of measurement: Based on Western Ontario and McMaster Universities Arthritis Index (WOMAC).</prim_outcome>
      <prim_outcome>Knee stiffness. Timepoint: Before treatment, week 4, week 8, and week 16. Method of measurement: Based on Western Ontario and McMaster Universities Arthritis Index (WOMAC).</prim_outcome>
      <prim_outcome>Blood level of immunologic factors VEGF IL23 IL17. Timepoint: Before studying and week 8. Method of measurement: Blood samples from patients will be taken for immunological tests before the study and at week 8. The blood samples will be stored at -80 degrees in the reference lab so they can be used for future studies as well.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: Before treatment, week 4, week 8, and week 16. Method of measurement: Based on Short Form (36) Health Survey (SF 36).</sec_outcome>
      <sec_outcome>The need for using painkillers. Timepoint: Before treatment, week 4, week 8, and week 16. Method of measurement: Based on the patient's medical history as well as the form listing the painkillers used by the patient.</sec_outcome>
      <sec_outcome>Side effects. Timepoint: Week 4, week 8, and week 16. Method of measurement: Based on the patient's medical history as well as the form about side effects filled out by the patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-06-21</approval_date>
        <contact_name>ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Shahid Fakouri Blvd., between Shahid Javan Sq. and Al Shahidi Sq., Mashhad, Khorasan Razavi Province Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
